drugset / Trial / NCT05245760
ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.
Timeline
- Start
- 2022-04
- Primary completion
- 2023-03
- Completion
- 2033-12
Outcome
Outcome not reported
Stopped (Business): “Funding unavailable.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Carboplatin | Small molecule | 2 unknown | — |
| Background | Paclitaxel | Small molecule | 50 mg/m2 | — |